← Back to Search

CAR T-cell Therapy

Pirtobrutinib + CAR T-cell Therapy for Mantle Cell Lymphoma

Miami, FL
Phase 2
Recruiting
Led By Michael Jain, MD, PhD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a histologically confirmed diagnosis of mantle cell lymphoma (MCL) will be eligible
Adult males or females who are 18 years of age or older at time of signing informed consent
Must not have
Patients with active CNS involvement of Mantle Cell Lymphoma
Inability of the participant to swallow and retain oral medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 48 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment for patients with a type of lymphoma that has come back or not responded to previous treatments. The treatment involves a type of therapy called CD19 CAR T-cell therapy

See full description
Who is the study for?
This trial is for people with a type of lymphoma called relapsed/refractory mantle cell lymphoma (R/R MCL) who qualify for standard CD19 CAR T-cell therapy. Specific eligibility details are not provided, but typically participants need to meet certain health standards and have no conflicting conditions.Check my eligibility
What is being tested?
The study is testing two treatments: Brexucabtagene Autoleucel, a form of CAR T-cell therapy, and Pirtobrutinib, a medication. It's an open-label trial where patients are randomly assigned to receive one of these interventions.See study design
What are the potential side effects?
While specific side effects aren't listed here, CAR T-cell therapies like Brexucabtagene Autoleucel can cause immune system reactions and Pirtobrutinib may lead to bleeding issues or infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with mantle cell lymphoma.
 show original
Select...
I am 18 years or older and can give informed consent.
 show original
Select...
I am eligible for a specific immune therapy (CAR T-cell) for my mantle cell lymphoma.
 show original
Select...
I can care for myself and am up and about more than 50% of my waking hours.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My Mantle Cell Lymphoma has spread to my brain or spinal cord.
 show original
Select...
I cannot swallow or keep down oral medication.
 show original
Select...
I had severe bleeding or heart rhythm problems with a previous BTK inhibitor treatment.
 show original
Select...
I have previously undergone CAR T-cell therapy.
 show original
Select...
I do not have serious or unmanaged heart conditions.
 show original
Select...
I have an active infection that is not being treated.
 show original
Select...
I am HIV positive.
 show original
Select...
I currently have an active CMV infection.
 show original
Select...
I am currently taking long-term steroids or immunosuppressants.
 show original
Select...
I have not had major surgery in the last 4 weeks.
 show original
Select...
I stopped taking pirtobrutinib because my disease got worse or due to side effects.
 show original
Select...
I need blood thinners like warfarin for my condition.
 show original
Select...
I have not had a stroke or brain bleed in the last 6 months.
 show original
Select...
I have an active autoimmune disease affecting my brain or spinal cord.
 show original
Select...
I have a history of a genetic bleeding disorder.
 show original
Select...
I have an active autoimmune condition affecting my blood cells.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 48 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 48 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-free survival (PFS) - Comparison between arm A and arm B
Progression-free survival (PFS) - Historical comparison
Secondary study objectives
Overall Response Rate (ORR)
Overall survival (OS)
Severe CRS
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment2 Interventions
Participants will recieve pirtobrutinib as bridging therapy from day -27 to day -7. Participants on Arm B (n=30) will discontinue pirtobrutinib after day -7 and will not receive concurrent pirtobrutinib ("con-none") between day -6 and 1-year post-CD19 CAR T-cell therapy.
Group II: Arm AExperimental Treatment2 Interventions
Participants will recieve pirtobrutinib as bridging therapy from day -27 to day -7. Participants randomized to Arm A (n=30) will continue to receive concurrent pirtobrutinib ("con-pirto"), starting at day -6 and continued until 1-year post-CD19 CAR T-cell therapy with brexucel.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pirtobrutinib
2020
Completed Phase 1
~250

Find a Location

Closest Location:Moffitt Cancer Center· Tampa, FL· 1119 miles

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
575 Previous Clinical Trials
144,965 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,697 Previous Clinical Trials
3,470,285 Total Patients Enrolled
Bankhead-Coley Florida Biomedical Research ProgramUNKNOWN
2 Previous Clinical Trials
217 Total Patients Enrolled
Michael Jain, MD, PhDPrincipal InvestigatorMoffitt Cancer Center
2 Previous Clinical Trials
54 Total Patients Enrolled
~40 spots leftby Aug 2029